Wegovy pill vs injection: what the trials show

The short answer: for weight management, the once-daily semaglutide tablet and the once-weekly injection produce similar average weight loss in separate trials, carry the same boxed warning, and differ mostly in convenience, label scope, and price. There is no head-to-head trial yet.

This Q&A covers evidence and access. Dosing belongs with your prescriber and the product label.

What exactly was approved?

Semaglutide has been available as a pill since 2019, when FDA approved Rybelsus tablets for type 2 diabetes. [6] In December 2025 a tablet version of Wegovy was added for weight management. The current Wegovy label covers both forms. [5] The full sequence is on the semaglutide regulatory timeline.

The two forms do not have identical indications. Both are approved, with diet and physical activity, to reduce excess body weight and maintain the reduction long term, and to lower the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. The injection is also approved for patients aged 12 and older and for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The tablets are approved for adults only. [5]

How much weight did people lose on the tablet?

Two phase 3 trials tested oral semaglutide in adults with obesity or overweight and no diabetes.

• OASIS 4 (25 mg daily, the approved top strength). 307 participants were randomized 2:1 to the tablet or placebo, with lifestyle support. At week 64, mean weight change was minus 13.6% with the tablet versus minus 2.2% with placebo. [1]
• OASIS 1 (50 mg daily, a higher strength that is not the approved product). 667 participants. At week 68, mean weight change was minus 15.1% versus minus 2.4%, and 85% of tablet-treated participants lost at least 5% of body weight versus 26% on placebo. [2]

And on the injection?

The benchmark is STEP 1: 1,961 adults with obesity or overweight and no diabetes. At week 68, mean weight change was minus 14.9% with the 2.4 mg weekly injection versus minus 2.4% with placebo. [3] That places the approved tablet and the injection within about a percentage point of each other, though the trials ran for different lengths and enrolled different people.

Has anyone compared them directly?

Not in a randomized trial. The closest evidence is an indirect treatment comparison published in 2026 that combined OASIS 4 and STEP 1 through their placebo arms. It found comparable efficacy across weight, cardiometabolic, and quality-of-life outcomes, with the injection ahead by about 1 percentage point on weight change, a difference the authors judged not clinically relevant. [4]

Read that result with its limits in mind. Indirect comparisons cannot fully adjust for differences between trials, and this one was funded and partly authored by the manufacturer. [4] Our guide to reading a peptide study explains why that matters.

Are side effects different?

The pattern is the same: mostly gastrointestinal. In OASIS 4, gastrointestinal adverse events occurred in 74.0% of the tablet group versus 42.2% on placebo. [1] In OASIS 1, at the higher 50 mg strength, the figures were 80% versus 46%. [2]

The label says the types and frequency of common adverse reactions with the 25 mg tablet were similar to those with the injection, where nausea was reported by 44% of patients versus 16% on placebo. Discontinuation for adverse reactions was 6.9% with the tablet versus 5.9% with placebo, and 6.8% with the injection versus 3.2% with placebo. [5] Both forms carry the same boxed warning about thyroid C-cell tumors seen in rodents. [5]

Which costs less?

At manufacturer self-pay prices in September 2026, the tablet is usually cheaper. The manufacturer's pharmacy lists Wegovy tablets at 149 USD a month for the 1.5 mg strength, 199 USD for 4 mg, and 299 USD for 9 mg and 25 mg. The Wegovy pen is 349 USD a month after an introductory offer of 199 USD for the first two fills through December 31, 2026. [7]

For Medicare Part D enrollees who qualify, the Medicare GLP-1 Bridge covers Wegovy injection or tablets at a 50 USD monthly copay from July 1, 2026, with prior authorization. [8] Insurance coverage, list prices, and telehealth program fees are broken out on the semaglutide cost page.

How do I get one?

The access path is the same for both forms: a licensed prescriber, in person or by telehealth, and a licensed pharmacy. Neither form is a controlled substance. Any product sold as "research" semaglutide is not an approved drug and is not lawful for human use.

If weight loss magnitude is the main goal, the semaglutide vs tirzepatide comparison is worth reading before choosing a form. The obesity condition page ranks every option by evidence, and the GLP-1 hub covers the whole class.